Masimo (NASDAQ:MASI) Raised to “Hold” at Wells Fargo & Company

Masimo (NASDAQ:MASI) was upgraded by analysts at Wells Fargo & Company to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other research firms have also recently commented on MASI. BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price for the company. in a report on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a report on Thursday, January 22nd. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Monday, December 1st. Finally, Wolfe Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Masimo presently has an average rating of “Hold” and a consensus price target of $181.17.

Masimo Trading Up 1.5%

NASDAQ MASI opened at $178.70 on Wednesday. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72. The business has a fifty day simple moving average of $155.01 and a 200 day simple moving average of $146.83. Masimo has a 12 month low of $125.94 and a 12 month high of $178.87. The firm has a market capitalization of $9.60 billion, a P/E ratio of -16.95, a PEG ratio of 1.78 and a beta of 1.21.

Institutional Trading of Masimo

A number of hedge funds and other institutional investors have recently made changes to their positions in MASI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Masimo by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares in the last quarter. Clearstead Advisors LLC increased its stake in shares of Masimo by 18.4% in the third quarter. Clearstead Advisors LLC now owns 470 shares of the medical equipment provider’s stock worth $69,000 after purchasing an additional 73 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Masimo by 12.9% during the 4th quarter. Hantz Financial Services Inc. now owns 655 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 75 shares during the period. Assetmark Inc. lifted its stake in shares of Masimo by 5.5% during the 4th quarter. Assetmark Inc. now owns 1,850 shares of the medical equipment provider’s stock valued at $241,000 after buying an additional 97 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Masimo by 5.3% during the 2nd quarter. ProShare Advisors LLC now owns 1,995 shares of the medical equipment provider’s stock valued at $336,000 after buying an additional 101 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Key Headlines Impacting Masimo

Here are the key news stories impacting Masimo this week:

• Positive Sentiment: Wells Fargo upgraded Masimo to a “hold,” which may bolster short-term investor confidence and support the stock. Masimo upgraded by Wells Fargo (Zacks)
• Positive Sentiment: The Federal Circuit has been reported to affirm aspects of Masimo’s earlier ITC win, a result that could preserve some enforcement leverage and potential remedies in the dispute with Apple. Federal Circuit affirms Masimo’s initial ITC win (MacTech)
• Neutral Sentiment: Coverage highlights the complexity and duration of the Apple–Masimo litigation, underscoring continued legal uncertainty that may keep volatility elevated until final rulings or settlements. Apple Watch Patent Battle: A Legal Odyssey Unfolds (DevDiscourse)
• Negative Sentiment: An ITC judge ruled that Apple’s redesigned Apple Watch blood-oxygen workaround does not infringe Masimo patents — a direct legal setback that could limit Masimo’s ability to block Apple devices or win damages on that design. ITC judge: Apple Watch redesign doesn’t infringe (Bloomberg Law)
• Negative Sentiment: Multiple outlets report the ITC finding that Apple’s workaround avoids Masimo patents, reinforcing near-term legal headwinds and uncertainty about enforceable remedies. ITC judge rules Apple Watch workaround does not infringe (MacRumors)

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.